$30.41 Million in Sales Expected for Veracyte Inc (NASDAQ:VCYT) This Quarter

Wall Street analysts expect Veracyte Inc (NASDAQ:VCYT) to announce $30.41 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Veracyte’s earnings, with estimates ranging from $29.80 million to $30.84 million. Veracyte posted sales of $23.47 million in the same quarter last year, which suggests a positive year-over-year growth rate of 29.6%. The firm is expected to issue its next quarterly earnings results on Monday, November 4th.

According to Zacks, analysts expect that Veracyte will report full year sales of $120.71 million for the current financial year, with estimates ranging from $120.13 million to $121.10 million. For the next financial year, analysts expect that the business will post sales of $134.86 million, with estimates ranging from $133.07 million to $138.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Veracyte.

Veracyte (NASDAQ:VCYT) last released its earnings results on Tuesday, July 30th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.04. Veracyte had a negative return on equity of 10.26% and a negative net margin of 11.01%. The firm had revenue of $30.14 million during the quarter, compared to analysts’ expectations of $29.20 million.

Several equities research analysts have recently issued reports on VCYT shares. ValuEngine lowered Veracyte from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research raised Veracyte from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a research note on Saturday, May 4th. Lake Street Capital started coverage on Veracyte in a research note on Wednesday, July 31st. They issued a “buy” rating and a $35.00 price objective for the company. TheStreet raised Veracyte from a “d” rating to a “c-” rating in a research note on Thursday, August 1st. Finally, Needham & Company LLC set a $34.00 price objective on Veracyte and gave the company a “buy” rating in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Veracyte has a consensus rating of “Buy” and a consensus target price of $25.06.

In related news, Chairman Bonnie H. Anderson sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $28.79, for a total transaction of $230,320.00. Following the completion of the sale, the chairman now directly owns 127,955 shares of the company’s stock, valued at approximately $3,683,824.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Evan/ Fa Jones sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $26.38, for a total value of $395,700.00. Following the sale, the director now directly owns 25,000 shares of the company’s stock, valued at $659,500. The disclosure for this sale can be found here. Insiders have sold a total of 31,000 shares of company stock valued at $836,660 over the last three months. 8.30% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in shares of Veracyte by 15.5% in the 2nd quarter. Renaissance Technologies LLC now owns 525,500 shares of the biotechnology company’s stock valued at $14,982,000 after acquiring an additional 70,700 shares during the period. Atika Capital Management LLC purchased a new position in shares of Veracyte in the 2nd quarter valued at $3,905,000. Bank of New York Mellon Corp increased its holdings in shares of Veracyte by 89.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 287,157 shares of the biotechnology company’s stock valued at $8,186,000 after acquiring an additional 135,902 shares during the period. Fiera Capital Corp increased its holdings in shares of Veracyte by 462.9% in the 2nd quarter. Fiera Capital Corp now owns 918,078 shares of the biotechnology company’s stock valued at $26,174,000 after acquiring an additional 754,988 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Veracyte by 33.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 221,763 shares of the biotechnology company’s stock valued at $6,323,000 after acquiring an additional 55,652 shares during the period. 97.01% of the stock is owned by hedge funds and other institutional investors.

Veracyte stock traded down $0.87 during midday trading on Wednesday, reaching $25.26. 429,313 shares of the stock traded hands, compared to its average volume of 672,615. The business’s fifty day moving average price is $27.80. Veracyte has a 12 month low of $8.77 and a 12 month high of $31.18. The company has a market cap of $1.22 billion, a PE ratio of -40.74 and a beta of 0.96.

Veracyte Company Profile

Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.

Further Reading: How does a margin account work?

Get a free copy of the Zacks research report on Veracyte (VCYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit